|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature显示文摘 | Stokkermans-Dubois J Jouary T Vergier B | 2006 | Dermatology2006，213，4： | 1 |
| 2 | Resection of bronchopulmonary cancers invading the left atrium benefit of cardiopulmonary bypass显示文摘 | Baron O Jouari J Sagan C | 2003 | Thorac Cardiov Surg2003，51，： | 1 |
| 3 | A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature显示文摘 | Stokkermans DJ Jouary T Vergier B | 2006 | Dermatology2006，213，4： | 1 |
| 4 | Segmental vitiligo as the possible expression of cutaneous somatic mosaieism: implications for common non-segmental vitiligo 显示文摘 | Taieb A Moriee-Picard F Jouary T | 2008 | Pigment Cell Melanoma Res2008，21，6： | 1 |
| 5 | Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo 显示文摘 | Taieb A Morice-Picard F Jouary T | 2008 | Pigment Cell Melanoma Res2008，21，： | 1 |
| 6 | Guidelines for the management of vitiligo: the European Dermatology Forum consensus显示文摘 | A. Taieb A. Alomar M. B?hm M.L. Dell’Anna A. De Pase V. Eleftheriadou K. Ezzedine Y. Gauthier D.J. Gawkrodger T. Jouary G. Leone S. Moretti L. Nieuweboer‐Krobotova M.J. Olsson D. Parsad T. Passeron A. Tanew W. van der Veen N. van Geel M. Whitton A. Wolker | 2012 | British Journal of Dermatology2012，，1： | 1 |
| 7 | Dabrafenib in BRAF -mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial显示文摘 | Axel Hauschild Jean-Jacques Grob Lev V Demidov Thomas Jouary Ralf Gutzmer Michael Millward Piotr Rutkowski Christian U Blank Wilson H Miller Eckhart Kaempgen Salvador Martín-Algarra Boguslawa Karaszewska Cornelia Mauch Vanna Chiarion-Sileni Anne-Marie Mar | 2012 | The Lancet2012，，9839： | 1 |
| 8 | Variant of TYR andautoimmunity susceptibility loci in generalized vitiligov显示文摘 | Taieb A Jouary T Ezzedine K | 2010 | N Engl JMed2010，362，18： | 1 |
| 9 | Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer显示文摘BACKGROUND Anti-epidermal growth factor receptor therapy is associated with skin adverse events not previously reported with conventional chemotherapy. Prophylactic actions are recommended, but routine clinical management of these toxicities and their impact on quality of life remain unknown. AIM To assess the dermatological toxicities reported after panitumumab initiation, their impact on the quality of life and the clinical practices for their management. METHODS Patients included in this prospective multicenter observational study were over 18 years of age and began treatment with panitumumab for wild-type KRAS metastatic colorectal cancer. The incidence of dermatological toxicities, clinical practices for their management and impact on quality of life were recorded during a 6-mo follow-up. RESULTS Overall, 229 patients (males, 57.6%;mean age, 66.2 years) were included. At day 15, 59.3% of patients had dermatological toxicity;the rate peaked at month 2 (74.7%) and decreased at month 6 (46.5%). The most frequent dermatological toxicities were rash/acneiform rash, xerosis and skin cracks. At least one preventive treatment was administered to 65.9% of patients (oral antibiotics, 84.1%;emollients, 75.5%;both, 62.9%). The rates of patients who received at least one curative treatment peaked at month 2 (63.4%) and decreased at month 6 (44.8%). The impact of the dermatological toxicities on quality of life was limited as assessed with Dermatology Life Quality Index scores and inconvenience visual analogic scale score. The rates of topical corticosteroids administration and visits to specialists were low. CONCLUSION The rates of the different skin toxicities peaked at various times and were improved at the end of follow-up. Nevertheless, their clinical management could be optimized with a better adherence to current recommendations. The impact of skin toxicities on patient’s quality of life appeared to be limited. | Olivier Bouche Meher Ben Abdelghani Jean-Luc Labourey Simon Triby René-Jean Bensadoun Thomas Jouary Gaétan Des Guetz | 2019 | World Journal of Gastroenterology2019，25，29： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员